Breast Necrosis in a Patient With Primary T-cell Non-Hodgkin Lymphoma

Publication date: Available online 25 June 2018Source: Cirugía Española (English Edition)Author(s): Ana Alicia Tejera Hernández, Joaquín Gómez Ramírez, Sonia Rivas Fidalgo, María Luisa Sánchez de Molina Ramperez, Mariano Díaz Miguel
Source: Cirugia Espanola - Category: Surgery Source Type: research

Related Links:

Infectious diseases are still a significant cause of morbidity and mortality worldwide. Despite the progress in drug development, the occurrence of microbial resistance is still a significant concern. Alternative therapeutic strategies are required for non-responding or relapsing patients. Chimeric antigen receptor (CAR) T cells has revolutionized cancer immunotherapy, providing a potential therapeutic option for patients who are unresponsive to standard treatments. Recently two CAR T cell therapies, Yescarta® (Kite Pharma/Gilead) and Kymriah® (Novartis) were approved by the FDA for the treatments of certain types ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Conditions:   Relapsed and Refractory B Cell Lymphoma;   Non-Hodgkin Lymphoma Intervention:   Biological: CD20 CAR-T Sponsor:   Shanghai Longyao Biotechnology Inc., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, is characterized by both clinical and molecular heterogeneity. Despite efforts to tailor therapy for individual patients, treatment remains uniform and a subset of patients have poor outcomes. The past decade has witnessed a dramatic expansion of our understanding of the genomic underpinnings of this disease, especially with the application of next-generation sequencing. In this review, the authors highlight the current genomic landscape of DLBCL and how this information provides a potential molecular framework for precision medicine-ba...
Source: Surgical Oncology Clinics of North America - Category: Surgery Authors: Source Type: research
Chem. Commun., 2019, Advance Article DOI: 10.1039/C9CC06603A, CommunicationCharmaine Hee, Diwei Ho, Amir Karton, Gareth Nealon, Jessica A. Kretzmann, Marck Norret, K. Swaminathan Iyer Polymers are an attractive anchoring platform for the synthesis of radioimmunoconjugates. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Chem. Commun. latest articles - Category: Chemistry Authors: Source Type: research
Abstract Polymers are an attractive anchoring platform for the synthesis of radioimmunoconjugates. They enable independent control over the amount of radioisotope loading and antibody attachment, which is pivotal in developing tailorable formulations for personalised medicine. Herein, we report the synthesis of p(HEMA-ran-GMA) for the conjugation of lutetium ions and rituximab as a functional platform for radioimmunotherapy. We demonstrate the suitability of this platform using non-Hodgkin's lymphoma cells. PMID: 31735949 [PubMed - as supplied by publisher]
Source: Chemical Communications - Category: Chemistry Authors: Tags: Chem Commun (Camb) Source Type: research
ConclusionRT is an effective and curative local treatment for early-stage FL and MZL at conventional and reduced radiation doses. Conventional-doses seems to be associated with local response improvement, without significant differences in PFS rates. Age, histology, and  response to RT may influence the PFS.
Source: Strahlentherapie und Onkologie - Category: Cancer & Oncology Source Type: research
Within the last decade, as interest has renewed in finding innovative ways to harness the immune system to treat cancer, chimeric antigen receptor (CAR) T cell therapy has risen to the helm in treatment of relapsed/refractory non-Hodgkin lymphoma (NHL). Engineering a patient's own T cells to directly target CD19-expressing lymphoma/leukemia cells has resulted in unprecedented response rates in heavily pre-treated patients, and the responses have proven durable for most NHL patients who achieve an early complete remission [1 –5].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
In this study, we investigated the feasibility of releasing this peptide into the tumor microenvironment using live attenuated Salmonella enterica, which has proven to be an ally in cancer therapy due to its high affinity for tumor tissue, its ability to activate the innate and adaptive antitumor immune responses, and its potential use as a delivery system of heterologous molecules. Thus, we expressed and released the cell-permeable Bax BH3 peptide from the surface of Salmonella enterica serovar Typhimurium SL3261 through the MisL autotransporter system. We demonstrated that this recombinant bacterium significantly decreas...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Condition:   Non Hodgkin Lymphoma Intervention:   Drug: Kymriah Sponsors:   University of Cologne;   Novartis Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Abstract Multiple myeloma (MM) is the second most prevalent hematologic malignancy after non-Hodgkin lymphoma and is currently considered incurable. Clinical ophthalmic manifestations of MM are rare but at the same time diverse. Ocular surface manifestations of multiple myeloma are uncommon.Conjunctival 'salmon patch' is a typical ocular surface ophthalmological sign with a distinct set of differential diagnoses, including most often ocular adnexal lymphoma.This case report presents a 33-year-old female with a relapse of MM manifesting as a conjunctival 'salmon patch'. The patient initially responded well to medic...
Source: Orbit - Category: Opthalmology Authors: Tags: Orbit Source Type: research
More News: Lymphoma | Non-Hodgkin's Lymphoma | Surgery